• Galapagos shareholder meetings held April 28, 2026 adopted all board-backed resolutions.
• Annual meeting endorsed annual report, remuneration report, reappointment of statutory auditor, mandate for auditor to provide assurance on CSRD sustainability reporting.
• Annual meeting backed board changes, including appointment of Henry Gosebruch as executive director, appointments of multiple independent non-executive directors, appointment of Devang Bhuva as non-executive director.
• Extraordinary meeting endorsed change of company name to Lakefront Biotherapeutics, with effectiveness set for May 8, 2026.
• Extraordinary meeting authorized board to buy back shares, renewed authorized capital by up to 20% of share capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galapagos NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604281601OMX_____CNEWS_EN_GNW1001178585_en) on April 28, 2026, and is solely responsible for the information contained therein.